Myou S, Fujimura M, Kamio Y, Ishiura Y, Tachibana H, Hirose T, Hashimoto T, Matsuda T
Third Department of Internal Medicine and Laboratory of Medicine, Kanazawa University School of Medicine, Kanazawa, Japan.
Am J Respir Crit Care Med. 1999 Sep;160(3):817-20. doi: 10.1164/ajrccm.160.3.9812065.
The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the usefulness of inhaled PDE3 inhibitors in the treatment of asthma, we investigated the bronchodilator effect of inhaled olprinone, a newly developed PDE3 inhibitor, in nine asthmatic patients. On three separate study days, olprinone, salbutamol, or vehicle was administered in a double-blind and randomized fashion, and pulmonary functions were assessed over 60 min. Significant increases in FEV(1) were observed until 45 min after inhalation of olprinone without adverse cardiovascular effects. Mean maximal increases in FEV(1) were 16.0 +/- 4.0 and 20.5 +/- 4.2% with olprinone and salbutamol, respectively. The bronchodilator effect of olprinone was greater than that of salbutamol in four of the nine patients. These results suggest that the inhaled PDE3 inhibitor has a bronchodilator effect in asthmatic patients.
局部应用磷酸二酯酶（PDE）3抑制剂对气道的影响尚不清楚。为了研究吸入性PDE3抑制剂在哮喘治疗中的有效性，我们调查了一种新开发的PDE3抑制剂——吸入用奥普力农对9例哮喘患者的支气管扩张作用。在三个不同的研究日，以双盲和随机方式给予奥普力农、沙丁胺醇或赋形剂，并在60分钟内评估肺功能。吸入奥普力农后45分钟内，FEV（1）显著增加，且无不良心血管效应。奥普力农和沙丁胺醇使FEV（1）的平均最大增加分别为16.0±4.0%和20.5±4.2%。9例患者中有4例，奥普力农的支气管扩张作用大于沙丁胺醇。这些结果表明，吸入性PDE3抑制剂对哮喘患者有支气管扩张作用。
